Savara (SVRA) Phase 3 Study of Molgradex for Treatment of aPAP Did not Meet its Primary Endpoint StreetInsider By John Harbison|2019-06-25T10:14:59-08:00June 12, 2019|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Savara (SVRA) Phase 3 Study of Molgradex for Treatment of aPAP Did not Meet its Primary Endpoint Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkXingEmail About the Author: John Harbison Related Posts
